CORRECTING and REPLACING Texas Oncology to Present Research on Advantages of Integrated Pharmacy Model at ASCO Quality Care Symposium

Presenters share research on patient impact and cost effectiveness
derived from integrated pharmacy data and protocols

DALLAS–(BUSINESS WIRE)–Second paragraph of release, author’s name should read Dr. Gury Doshi
and Dr. Lalan Wilfong
(instead of Dr. Lalan Wilfong)

The corrected release reads:


Presenters share research on patient impact and cost effectiveness
derived from integrated pharmacy data and protocols

Physicians from Texas Oncology will present findings from research
projects at ASCO Quality Symposium this week highlighting benefits of an
integrated pharmacy model, including studies regarding oral oncolytic
therapies, compliance and efficacy with anti-nausea medications, and use
of pegfilgrastim.

Abstract summaries:

Oral oncolytic therapies, medically integrated pharmacy, Dr. Gury
Doshi and Dr. Lalan Wilfong

Texas Oncology’s medically
integrated pharmacy (MIP) uses shared knowledge to improve patient
experience, patient adherence, and while reducing costs from less waste,
fewer side effects, and fewer hospitalizations. The team consists of
oncologists, oncology nurses, advanced practice providers,
nutritionists, financial counselors, and specially trained pharmacy
staff using real-time access to the patient’s electronic medical and
pharmacy records when oral therapy is prescribed. The team manages the
end to end process of administering, monitoring, and side effects follow
up for oral therapies to deliver patient-focused solutions that drive
industry-leading outcomes and contain costs. Adherence to therapy is
over 92 percent for the seven most commonly prescribed oral oncolytic
drugs. Surveys reveal 96 percent patient satisfaction with the medically
integrated pharmacy.

Side effects control, medically integrated pharmacy, Dr. Lalan Wilfong
integrated pharmacists embedded in two community-based cancer centers
developed an interchange protocol to control chemotherapy induced nausea
and vomiting (CINV). More than 350 patients were treated over a
nine-month period, with follow up to evaluate CINV. Eighty-nine percent
of patients had complete control of nausea with only 11 percent
reporting nausea greater than a three on a Likert scale. The
pharmacist-driven approach, within an integrated care model, resulted in
excellent control of CINV.

Guidelines compliance in prescribing anti-nausea medications, Dr.
Lalan Wilfong

With a goal of achieving greater compliance,
Texas Oncology pharmacists evaluated emetogenic risk of chemotherapy
according to NCCN guidelines. Pharmacists then used a therapeutic
interchange protocol to adjust anti-nausea medications. As a result, 99
percent of patients with minimal nausea were not initially given NK-1
inhibitors, and 97 percent of highly emetogenic regimens received
guideline compliant therapy.

Pegfilgrastim use, Dr. J. Russell Hoverman
As a participant
in value-based care programs including the Oncology Care Model and
payer-based programs, Texas Oncology reviewed usage of pegfilgrastim.
After reviewing claims data, physicians were presented with ASCO
guidelines, educational materials, and non-use recommendations according
to national guidelines. An internal review process was launched.
Substantial reductions in pegfilgrastim use were achieved by following
appropriate guideline-based use.

About Texas Oncology

As an independent oncology practice with more than 420 physicians and
175 locations, Texas Oncology’s community-based care offers patients
high-quality cancer care without compromise, including access to
leading-edge technology, advanced treatment options, and access to
clinical trials. As a primary participant in US Oncology Research, Texas
Oncology played a role in more than 70 FDA-approved therapies, about
one-third of all cancer therapies approved by the agency to date.

Texas Center for Proton Therapy, Texas Breast Specialists, and Texas
Center for Interventional Surgery are part of Texas Oncology. Texas
Oncology is a member of The US Oncology Network, one of the nation’s
largest community-based cancer treatment and research networks. For more
information, visit


Texas Oncology
Ed Bryson, 512-592-8190